HWBIO’s MeiboRevive™ Vectored Thermal Pulsation System Series Shines at the 30th Scientific Congress of Ophthalmology of the Chinese Medical Association

01 Focusing on the Frontier, the Congress Opens

In September in Tianjin, the sky was high and vast, and the Haihe River shimmered. On September 10, the 30th Scientific Congress of Ophthalmology of the Chinese Medical Association (CCOS 2026), hosted by the Chinese Medical Association and its Ophthalmology Branch, and organized by the Tianjin Medical Association and its Ophthalmology Branch, grandly opened at the National Convention and Exhibition Center (Tianjin). With the theme “Precision in Vision, Brilliance for the Future,” this year’s congress closely focused on the frontiers, hot topics, and challenges in ophthalmology and its subspecialties, bringing together more than 1,000 renowned ophthalmic experts from China and abroad and over 10,000 delegates to participate in this top annual academic event in China’s ophthalmic community.

As an innovative company deeply engaged in the dry eye treatment field, HWBIO made a major appearance with its core product series, the MeiboRevive™ Vectored Thermal Pulsation System, at Booth C385, Hall S9. With leading technology and professional services, it became one of the highlights on the first day of the congress.

02 Major Appearance: Precisely Addressing Pain Points in Dry Eye Diagnosis and Treatment

On the first day of the congress, HWBIO’s booth was bustling. Its independently developed MeiboRevive™ Vectored Thermal Pulsation System, with core technological advantages, attracted many attending ophthalmic experts, clinicians, and industry partners to stop by for consultations and in-depth exchanges.

The product is a flagship achievement of HWBIO’s deep cultivation in the dry eye field. Supported by proprietary core vectored thermal pulsation technology, it precisely targets dry eye disease caused by meibomian gland dysfunction (MGD). The product innovatively adopts a synergistic treatment model of “precision heating + pulsed massage”: on one hand, through proprietary temperature-control technology, it achieves constant-temperature heating of the meibomian gland area, efficiently softening obstructed lipids; on the other hand, combined with rhythmic pulsed massage, it deeply clears the meibomian glands, promotes lipid discharge, and rebuilds a healthy tear film. This innovative solution directly targets the core etiology of dry eye, providing a new safe, effective, and standardized option for clinical dry eye diagnosis and treatment.

03 Immersive Experience Zone: Three-Dimensional Interaction Demonstrates Technological Strength

HWBIO specially created a dedicated experience zone for the MeiboRevive™ Vectored Thermal Pulsation System, innovatively building a three-dimensional interactive model of “technical explanation + hands-on demonstration + on-site experience.” A senior technical team was on hand throughout the event, carefully explaining the system’s technical principles, clinical application advantages, applicable scenarios, and operating protocols. Many physicians spoke highly of it after firsthand experience, believing that the system is easy to operate, comfortable for treatment, and significantly effective. It can effectively address clinical pain points in dry eye diagnosis and treatment and effectively improve dry eye diagnosis and treatment efficiency and patient satisfaction. The atmosphere for on-site consultations and business discussions was very lively.

04 Deepening Dry Eye Diagnosis and Treatment to Safeguard National Eye Health

This appearance at CCOS 2026 was not only a concentrated showcase of HWBIO’s core technologies and product strength, but also an important opportunity to connect with clinical needs and promote industry-academia-research translation. As an innovative company focused on high-end ophthalmic medical devices, HWBIO has always been guided by clinical needs, continuously deepening its work in the dry eye treatment field. Relying on independent R&D and technological innovation, it continuously iterates and optimizes its product portfolio.

In the future, HWBIO will continue to deepen its work in ophthalmic healthcare, closely following the academic direction of the CCOS congress, “Precision in Vision, Brilliance for the Future,” deepening technological R&D and clinical application, helping comprehensively upgrade the level of dry eye diagnosis and treatment, and contributing professional strength to safeguarding the eye health of the people across the full life cycle.